

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2020 (02.01.2020)



(10) International Publication Number
WO 2020/002320 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) A61P 7/02 (2006.01)
A61K 31/4427 (2006.01) A61P 23/02 (2006.01)
A61K 31/4439 (2006.01) A61P 9/00 (2006.01)
A61P 27/06 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/EP2019/066811

(22) International Filing Date:

25 June 2019 (25.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18180137.4 27 June 2018 (27.06.2018) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(71) Applicant: **ETH ZUERICH** [CH/CH]; Raemistrasse 101, CH-8092 Zuerich (CH).

(72) Inventors: **GOBBI, Luca**; c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel (CH). **GRETHER, Uwe**; c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel (CH). **KRETZ, Julian**; c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel (CH). **AMETAMEY, Simon, M.**; c/o ETH Zuerich Raemistrasse 101, 8092 Zuerich (CH).

(74) Agent: **POMERANC, Didier** et al.; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2



(I)

(57) Abstract: The invention relates to a compound of formula (I) wherein A, A², X and R¹-R³ are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament, due to its inhibition of cannabinoid receptor 2.

WO 2020/002320 A1